You are here: Industry Insights > Copiktra

News List

Secura Bio Announces Copiktra (duvelisib) Strategic Focus On T-cell Lymphoma And Voluntary U.S. Withdrawal Of The Relapsed Or Refractory Follicular Lymphoma Indication Drugs
December 08, 2021
Secura Bio, Inc. (Secura Bio) - (www.securabio.com), an integrated pharmaceutical company dedicated to the worldwide development and commercialization of impactful oncology therapies...
Five new meds recommended in March CHMP decisions pharmatimes
March 30, 2021
The European Medicines Agency’s (EMA) human medicines committee (CHMP) has recommended five new medicines for approval at its March meeting, as well as six recommendations of current indications.
Verastem to divest Copiktra rights to Secura Bio for up to $381m pharmaceutical-technology
August 12, 2020
Biopharmaceutical company Verastem has signed a definitive agreement to divest the global commercial and development rights for Copiktra (duvelisib) to Secura Bio in a deal valued at up to $381m.
Sanofi to develop Verastem’s Copiktra in certain regions pharmaceutical-technology
July 29, 2019
Sanofi has signed a licensing agreement to develop and commercialise Verastem Oncology’s Copiktra (duvelisib) in Russia and CIS, Turkey, the Middle East and Africa.
US clears Verastem’s Copiktra for blood cancers pharmatimes
September 27, 2018
Verastem Oncology’s Copiktra has been approved in the US for the treatment relapsed or refractory chronic lymphocytic leukaemia/small...